CannTrust (TSX:TRST) Director Steps Down for This Pot Stock

CannTrust (TSX:TRST)(TSX:CTST) director John Kaden resigned on Monday from the company’s board of directors to focus on Navy Capital Green.

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

CannTrust (TSX:TRST)(NYSE:CTST) director John Kaden resigned today from the company’s board of directors. Kaden had joined the corporation’s board one year ago in October 2018. Kaden was also a vital member of the select committee, which investigated the cannabis production scandal earlier this year.

In July, Health Canada discovered secret grow rooms and unlicensed cultivation in CannTrust facilities. The stock’s board of directors responded by investigating the leadership responsible for the unauthorized production activities. Kaden, along with the rest of CannTrust’s board of directors, fired its former CEO Peter Aceto with cause.

Health Canada suspended CannTrust’s licence to produce and sell cannabis products in September. The licence suspension has lowered the stock’s revenue potential — as it can no longer generate revenue from marijuana. Moreover, the company is side-lined at a crucial time for pot players to compete for market share.

The company suffered even more losses this month when it was forced to destroy cannabis plants and inventory worth $77 million, some of which clients had returned. As a result, the stock’s price declined by 75% in just a few months.

Kaden optimistic on CannTrust remediation

CannTrust is still moving toward regaining its cannabis licence. After the internal investigation, the company has been working with Health Canada on completing a remediation plan, which Kaden no doubt helped write.

It is not clear if the legal problems at CannTrust influenced Kaden’s decision to step down from his short tenure on the board of directors. Regardless, the legal issues certainly did not encourage him to stay on the board. The statement Kaden released regarding his resignation only commented favourably on the ability of CannTrust to regain its licenses:

“With its remediation plan now underway, I believe CannTrust is well-positioned to fulfil its commitments to both bring the company into full regulatory compliance and seek the full reinstatement of its licences.”

This statement implies that Kaden felt the timing of his resignation was, in part, related to CannTrust’s progress toward legal remediation. Hopefully, CannTrust will continue to move in the direction of regulatory compliance without Kaden on the team.

John Kaden to focus on Navy Capital Green

John Kaden is also the co-founder, managing partner, and chief investment officer of Navy Capital Green Management LLC. Navy Capital is an investment management firm, which, as of November 2018, had a $14.7 million stake in MariMed (OTC:MRMD), a Canadian cannabis producer.

MariMed’s market cap is only slightly lower than CannTrust’s at $213.68 million. The price on its stock currently sits at just under $1 per share. Perhaps Kaden will take a more active role in Navy Capital Green’s partnership with MariMed now that he is no longer on CannTrust’s board of directors.

With Kaden’s experience and reputation, MariMed could very well be a top cannabis stock in the next few years. The stock certainly has an advantage over CannTrust after the legal controversy.

MariMed began designing and developing marijuana cultivation centres and dispensaries as far back as 2012. Now that the industry is officially legal, MariMed stands as a first mover in hemp CBD and precision-dosed cannabis brands.

Cannabis investors should keep an eye on John Kaden and the MariMed venture stock — they might lead the industry sooner than you’d think!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Debra Ray has no position in any of the stocks mentioned.

More on Stocks for Beginners

Family relationship with bond and care
Dividend Stocks

TFSA Investors: 3 Cheap Canadian Stocks for Retirees

These three Canadian stocks are super cheap for retirees looking for a great buy that will last the test of…

Read more »

A airplane sits on a runway.
Stocks for Beginners

Are Airline Stocks a Good Buy in December 2023?

Does the recent broader market recovery make Canadian airline stocks attractive to buy in December 2023? Let’s find out.

Read more »

edit Safety First illustration
Stocks for Beginners

For Friday: Safe Stocks to Buy in Canada for December 2023

The safest Canadian stocks may not be as obvious as it seems. Here are two safe stocks that have delivered…

Read more »

Value for money
Stocks for Beginners

2 Top Canadian Value Stocks in December 2023

Buying these top Canadian value stocks in December 2023 can help you expect big returns on investments in the long…

Read more »

data analytics, chart and graph icons with female hands typing on laptop in background
Stocks for Beginners

Where to Invest $1,000 in December 2023

These stocks are the perfect option for those seeking to put some cash away, mainly because you won't see a…

Read more »

data analyze research
Stocks for Beginners

The 3 Top-Performing TSX Stocks in November 2023 (Are They Still Buys?)

These TSX stocks proved to be the best of the best over the last month. But the question remains as…

Read more »

railroad with nature background
Dividend Stocks

Buy 32 Shares in This Top Dividend Stock for $701.12 in Passive Income

You could be looking at dividend stocks all wrong. Which is why it's important to be clear about what makes…

Read more »

Dots over the earth connecting the world
Tech Stocks

Is Constellation Software Stock Worth a Buy in December?

Constellation stock (TSX:CSU) is up 46% in the last year alone, but after an earnings miss should investors still consider…

Read more »